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Advances  in  the  management  of non-small  cell  lung  cancer  (NSCLC)  over  the  past  30 years  have  led  to
small  increases  in  5-year  survival  rates  across  Europe,  though  further  improvements  may  require  new
treatment  strategies.  In  order  to improve  efﬁciency  and  reduce  the  cost  of  development,  future  trials
for  new  targeted  agents  in NSCLC  should  aim  to recruit  patients  on  the  basis of tumour  biology  rather
than  clinical  characteristics.  However,  identiﬁcation  of  predictive  biomarkers  is  required  to maximise
the  beneﬁts  of  new  approaches  and  expedite  the  drug  development  process.  Nevertheless,  the  NSCLC
landscape  is changing  rapidly,  and  recent  improvements  in  our  understanding  of the  molecular  biology ofung  cancer
anagement
olecular proﬁling
utcomes
athogenesis
the  disease  will  help  in  the  identiﬁcation  of novel  targeted  agents  as well  as assisting  in  the  development
of  personalised  strategies  for the  numerous  small  subsets  of  deﬁned  NSCLC.  Progress  in  imaging  and
treatment  delivery  is also likely  to  improve  outcomes  for patients  with  the disease.  This  article  outlines
recent  progress  in  the  treatment  of NSCLC,  identiﬁes  current  challenges  and  describes  proposals  for
improving  the  future  management  of  the  disease.  It is hoped  that implementation  of some  of these
ay  to
he Areatment strategies  will  go some  w
© 2013 T
. Introduction
Despite advances in the understanding of tumour biology in
ecent years, lung cancer mortality in Europe has remained largely
nchanged over the past three decades, underlying the need for
ew treatment strategies [1,2]. Earlier diagnosis is also important,
ince outcome is primarily related to stage at diagnosis, with 5-year
urvival rates being over 70% for those with stage I disease falling
o less than 5% for stage IV. Further challenges for improving NSCLC
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outcome include integration of new advances in clinical, patholog-
ical and molecular aspects into the management of the condition,
since the landscape is changing rapidly.
2. Molecular pathology of NSCLC
Four main histological types of lung cancer are recognised: squa-
mous cell carcinoma, adenocarcinoma and large cell carcinoma –
known collectively as NSCLC – and small cell lung cancer (SCLC)
[3,4]. However, mixed histology also occurs, complicating diag-
nostic evaluation. Nevertheless, the use of molecular analytical
techniques in recent years has improved histological typing in lung
Open access under CC BY-NC-ND license. cancer, especially in adenocarcinoma [3,5,6], with immunohisto-
logical markers such as cytokeratins (e.g. CK5/6) or transcription
factors (e.g. p63, TTF1) being used to assist in the identiﬁca-
tion of different lung cancer subtypes in small biopsies where
differentiation is not obvious.
ND license. 
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Table  1
Adenocarcinoma classiﬁcation proposed by the IASLC/ATS/ERS.
• Preinvasive lesions
©  Atypical adenomatous hyperplasia
© Adenocarcinoma in situ (≤3 cm [formerly BAC])
  Non-mucinous
 Mucinous
 Mixed mucinous/non-mucinous
•  Minimally invasive adenocarcinoma (≤3 cm lepidic predominant tumour
with ≤5 mm invasion
© Non-mucinous
© Mucinous
© Mixed mucinous/non-mucinous
•  Invasive adenocarcinoma
©  Lepidic predominant (formerly non-mucinous BAC pattern, with
>5 mm invasion)
© Acinar predominant
©  Papillary predominant
©  Micropapillary predominant
©  Solid predominant with mucin production
• Variants of invasive carcinoma
©  Invasive mucinous adenocarcinoma (formerly mucinous BAC)
© Colloid
© Foetal (low and high grade)
© Enteric
Reproduced with permission from Travis et al. [7].
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Recently, a new classiﬁcation of lung adenocarcinomas has been
roposed by the International Association for the Study of Lung
ancer, the American Thoracic Society and the European Respira-
ory Society (Table 1) [7]. The revised classiﬁcation recognises that
istological distinctions can be made between different prognostic
ubtypes, and that genetic alterations and response to therapy can
e suggested by tumour pathology. It should be noted that diag-
osis is made primarily on the basis of ﬁne needle core biopsy or
ronchial biopsies, limiting the amount of tissue available for iden-
ifying different genetic alterations. Alternative biopsy methods
hould be considered, therefore, if molecular testing is planned. An
lgorithm, employing a minimal set of markers, is recommended
or the diagnosis of lung cancer subtype in order to maximise the
umour tissue available for selected driver mutation research [7,8].
he new classiﬁcation has been validated in a number of studies
orldwide, including Europe [9,10]; however, its acceptance has
een variable and more data may  be required before it can be used
o select patients for biomarker testing. Nevertheless, as new data
merge, the revised classiﬁcation is expected to improve prognostic
ssessment for patients with adenocarcinoma, allowing subtyping
o be used to stratify patients for treatment [10,11]. Recent stud-
es characterising genomic alterations in NSCLC will also highlight
ew potential targets for treatment of the condition [12,13].
.  Use of biomarkers in NSCLC and the application of
ext-generation sequencing
Predictive  biomarkers are needed in NSCLC in order to max-
mise the beneﬁts of new treatment strategies and expedite drug
evelopment. Ideally, biomarkers should be speciﬁc, adaptable
or standard clinical use and present only in tumour tissue. A
ood understanding of the molecular biology of the target is
lso required for biomarker development due to the existence of
ultiple, inter-related signalling pathways. Biomarker studies are
ifﬁcult to perform for a number of reasons, including regulatory
ssues and tumour heterogeneity, with markers for both poor and
ood prognosis being found in the same tumour [14,15]. Addition-
lly, intellectual property rights for assays can be a barrier to the
linical implementation of biomarkers and may  limit drug develop-
ent for rare mutations (e.g. frequencies <1%). Consequently, forr 82 (2013) 375– 382
widespread clinical application, the development of inexpensive
and reproducible assays in parallel with drug development (com-
panion diagnostics) is required. Collaboration between centres is
also needed in order to standardise biomarker analyses and limit
false positive or negative outcomes.
A number of predictive biomarkers for NSCLC have already
been introduced into clinical practice. The most well established of
these are epidermal growth factor receptor (EGFR) mutations and
anaplastic lymphoma kinase (ALK) rearrangements, commonly in
the form of the echinoderm microtubule-associated protein-like
4-anaplastic lymphoma kinase (EML4-ALK) fusion oncogene [16].
EGFR activating mutations are detectable in around 10% of patients
with NSCLC in Western Europe [17], the most common of which
occur in exons 19–21 and confer sensitivity to the tyrosine kinase
inhibitors (TKIs) erlotinib and geﬁtinib [18]. T790M, another fre-
quently found EGFR mutation, is associated with TKI resistance
and is present in around 50% of patients treated with EGFR TKIs
at disease progression [19,20]. Recent data suggest that this muta-
tion may  be present at baseline rather than developing de novo
after therapy [21]. EML4-ALK rearrangements are found in 2–7%
of NSCLCs [22], most commonly in adenocarcinoma tumours from
young people (<65 years old) who are light smokers or who have
never smoked [23,24]. Other biomarkers thought to be associated
with addiction to oncogenic driver mutations and that are predic-
tive of response to speciﬁc agents in NSCLC include BRAF, HER2,
ROS1, FGFR1 and MET. KRAS is a driver mutation for which no spe-
ciﬁc targeted drug has yet been identiﬁed, and is thought to confer
relative resistance to EGFR TKIs [25–32]. More evidence is required
to validate biomarkers such as PIK3CA, ERCC1, MSH2, TS, BRCA1
and RRM1 [33,34].
Testing  of adenocarcinomas for EGFR mutation and ALK
rearrangement is now recommended in current guidelines and
is undertaken routinely in many centres [35]. The only validated
assay for detecting ALK rearrangement at present is ﬂuorescence
in situ hybridisation (FISH), though good results have recently been
achieved using an immunohistochemistry assay, which may be
more applicable to routine testing [36]. DNA mutational analysis
is the preferred method to assess EGFR status [37–39]. As routine
testing for increasing numbers of mutations is likely in the future,
the quality and availability of tissue samples could well become an
issue [40].
One  area that has seen an explosion in research in recent years
is next-generation sequencing (NGS), which has the ability to fully
sequence large numbers of genes in a single test (genome-wide
analysis) with high sensitivity and at relatively low cost [41,42].
The genes identiﬁed can then be validated by re-sequencing, which
can be used to help identify patients for particular treatments. A
further important application for NGS in the future is the detec-
tion of mutations in body ﬂuids, circulating tumour cells (CTCs),
plasma or sera, since the mutations may  be highly correlated with
the primary tumour [43]. Sampling at different time points using
this method may  help to identify mutations evolving after different
lines of treatment. NGS has already been adopted in some centres
and may  be used in the future to develop companion diagnostic
tests for new drugs [44]. NGS holds great promise for the future,
though the technology is not yet being used to guide treatment in
NSCLC. Problems associated with the uptake of NGS include the lack
of central regulation and standardisation for the platforms used,
the interpretation and validation of ﬁndings, reimbursement and
the ﬁnancial implications of identifying rare mutations.
4.  Current treatment options and new developments for
NSCLC  in Europe
Current  treatment for NSCLC in Europe is based primarily on
European Society for Medical Oncology (ESMO) guidelines [35], and
R. Stahel et al. / Lung Cancer 82 (2013) 375– 382 377
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iFig. 1. Mechanisms of tyrosine kinase inhibitor-acquired resistance. ALK, anapla
eproduced with permission from Lovly and Pao [60].
s selected according to molecular subtype, performance status (PS)
nd comorbidity. However, local adaptations to treatment selection
ccur due to differing reimbursement policies and access to drugs.
urthermore, drug costs for long-term treatment are likely to play
n increasingly important role in the future, particularly in the case
f maintenance treatment for metastatic disease.
The recommended ﬁrst-line treatment for metastatic NSCLC is
latinum-based chemotherapy for all patients with PS 0–2, with
n EGFR TKI being given to those with tumours bearing an activat-
ng (sensitising) EGFR mutation [35,45]. For healthy patients with
tage I–II NSCLC, lobectomy is the treatment of choice. Adjuvant
isplatin-based chemotherapy is recommended for patients with
tage II–III NSCLC after radical resection according to the 7th TNM
Tumour, Nodes, Metastasis) classiﬁcation [46]. Current guidelines
or patients with stage III disease recommend the use of chemother-
py and radiotherapy, either sequentially or (preferably) concur-
ently [46]. However, treatment for stage III NSCLC is particularly
hallenging due to patients’ comorbidities and tumour hetero-
eneity. Although treatment approaches for stage III NSCLC differ
onsiderably between regions and centres, neoadjuvant (chemo-
radiotherapy followed by surgery remains a standard option in
elected patients with resectable stage IIIA NSCLC. New drug devel-
pment and research into the optimum chemo-radiation strategies
or locally advanced NSCLC is also problematic due to the fact that
atients are potentially curable and may  not be willing to enrol
n clinical trials. Novel approaches currently being investigated in
tage III NSCLC include immunomodulatory strategies, agents act-
ng on the cell cycle (e.g. aurora kinase inhibitors) and novel cyto-
tatics [47,48]. ‘Window of opportunity’ trials undertaken before
hemotherapy or chemo-radiotherapy may  be a useful means of
esting new agents or strategies in this population. Such trials allow
he efﬁcacy of novel therapies to be investigated before the devel-
pment of resistance arising from prior therapy [49]. Although this
pproach raises possible ethical concerns relating to the use of an
gent of indeterminate efﬁcacy when standard therapies are avail-
ble, window trials, if carefully controlled, can provide valuable
nformation on the activity of new treatments for NSCLC [49,50].mphoma kinase; pEGFR, phosphorylated epidermal growth factor receptor [59].
The use of radiotherapy in lung cancer has seen a number of
advances in recent years, with kinetics as well as heterogeneity of
tumours being taken into account [51–53]. Uptake of radionuclides
can also vary within tumours due to differing vascularisation. This
presents the possibility of targeting different parts of the tumour
with varying amounts of radiation to deliver higher doses with less
toxicity [54]. Further possible future developments in radiotherapy
are the combination of radiotherapy with targeted agents [55], and
the use of proton-based technology, since such delivery improves
target volume distribution and is more lung-sparing than photon-
based delivery. Imaging biomarkers such as ﬂuorodeoxyglucose
(FDG)-positron emission tomography (PET) are also likely to be
used increasingly in the future to predict an early response to radio-
therapy, with changes in FDG uptake by the primary tumour found
to be signiﬁcantly predictive for 2-year survival in stage III NSCLC
during the ﬁrst week of (chemo-)radiotherapy [56].
5.  Clinical challenges of drug resistance in advanced NSCLC
Although  cytotoxics like cisplatin have been used in the treat-
ment of NSCLC for several decades, the mechanism(s) underlying
resistance to these agents are poorly understood. Nevertheless, a
number of predictive biomarkers for resistance to cytotoxics are
being investigated, including ERCC1 and RRM1. Data suggest that
patients with low levels of RRM1 or ERCC1 expression may  respond
better to carboplatin/gemcitabine [57,58]. However, current data
are not robust, particularly for ERCC1 due to the lack of speciﬁcity of
current antibodies [59]; prospective validation is needed, therefore,
before routine testing for ERCC1 or RRM1 can be recommended.
Mechanisms of resistance to TKIs include oncogene-dependent
second-site  mutations or gene ampliﬁcation and oncogene-
independent bypass tracks (Fig. 1) [60]. Resistance also arises
from tumour heterogeneity, since mutations are not found in
every tumour cell and there could be outgrowth of subpopulations
with rare mutations under treatment pressure, leading to acquired
resistance [61]. In addition, resistance can occur as a result of phar-
macokinetic factors due to decreases in drug levels, with differences
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Table  2
Novel  targets for drug treatment in non-small cell lung cancer and agents in development.
Target Agent Company Phase of development
EGFR GA201 Roche I
HER2  Afatinib (BIBW2992) Boehringer Ingelheim III
PF-00299804 Pﬁzer II
HER3  MM-121 Merrimack Pharmaceuticals I/II
U3-1287  (AMG888) U3 Pharma/Amgen I/II
IGF-1R  Figitumumab (CP-751,871) Pﬁzer III
OSI-906  OSI Pharmaceuticals/Astellas II
R1507  Roche II
Cixutumumab (IMC-A12) ImClone Systems I/II
AMG-479 Amgen I/II
XL-228  Exelixis I
HGF  AMG102 Amgen II
MET  MetMAb Roche II
XL880  Exelixis II
Cabozantinib (XL184) Exelixis II
ARQ-197  ArQule I
PI3K  XL-147 Exelixis/Sanoﬁ I
GDC-0941 Genentech I
PI3K/mTOR  XL-765 Exelexis/Sanoﬁ I
AKT  MK-2206 Merck I
PARP-1  Iniparib BiPar/Sanoﬁ Aventis II/IIIII
Veliparib Abbot I/II
Olaparib  AstraZeneca
TRAIL  Mapatumumab GSK II
Conatumumab Amgen II
CS-1008  Daiichi Sankyo II
PRO95780 Genentech II
AMG655  Amgen I/II
Hsp90  Ganetespib (STA-9090) Synta Pharmaceuticals II/III
IPI-504  Inﬁnity II
CDK  PD0332991 Pﬁzer II
Seliciclib  (CYC202) Cyclacel II
HDAC  Vorinostat Pantheon II
CDK, cyclin dependent kinase; EGFR, epidermal growth factor receptor; HDAC, histone deacetylase; HER2, human epidermal growth factor receptor 2; HER3, human epidermal
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crowth  factor receptor 3; HGF, hepatocyte growth factor; Hsp90, heat-shock protein
ARP-1, poly(ADP-ribose)polymerase-1; PI3K, phosphatidylinositol 3-kinase; TRAIL
ccurring between patients; however, drug concentrations within
umours are not well understood.
The  T790M mutation is one of the major mechanisms of resis-
ance to erlotinib and geﬁtinib [62]. The use of irreversible pan-HER
gents (e.g. neratinib, afatinib) to overcome T790M EGFR resis-
ance has not been encouraging, with very low response rates being
bserved [63,64]. Speciﬁc EGFR T790M inhibitors are also in devel-
pment, though there are no clinical data with these agents to date
65]. The lack of success with targeting this mutation thus far may
e due to the fact that its expression is not well understood, and this
ighlights the need for caution when identifying resistance genes
ince they may  not be activated in vivo.
The optimum management for patients whose disease pro-
resses after TKI therapy is unclear, and chemotherapy is the
nly approved systemic treatment at present. One strategy cur-
ently under investigation in this population is to continue TKI
herapy beyond progression, using local treatment such as radio-
herapy when needed, thus delaying a change in systemic therapy.
lthough there are no prospective data investigating TKI main-
enance beyond progression, the results of retrospective studies
uggest that this strategy may  improve both response rate and
urvival [66,67].
A  further approach for patients with TKI-resistant tumours is
he combination of targeted agents. Indeed, the ongoing trial of
etuximab plus afatinib has demonstrated clinical beneﬁt in 75%F-1R, insulin-like growth factor 1 receptor; mTOR, mammalian target of rapamycin;
our necrosis factor-related apoptosis-inducing ligand.
of  patients with TKI-resistant NSCLC [68]. However, the use of a
combination of targeted agents has been problematic to date due
to toxicity. Consequently, the addition of a cytotoxic to a targeted
agent may  be a more promising strategy both in patients with TKI-
resistant tumours [69] and upfront in untreated patients [70].
6.  Novel targets for drug treatment in NSCLC
The biology of the different mutations in NSCLC is complex and
validation of the various targets is challenging. Hundreds of new
mutations have been identiﬁed in NSCLC in recent years, particu-
larly non-hot spot mutations, which are present in 20–30% of NSCLC
tumours, though establishing the relevance of these mutations is
difﬁcult. An improved understanding of these gene alterations is
needed in order to assist in the identiﬁcation of new therapeu-
tic targets leading to improved clinical outcomes. This will require
translational laboratory research to establish underlying oncogene
addiction.
Despite the complexity of the molecular biology of NSCLC, a vast
array of new targets for NSCLC drug treatments are being investi-
gated (Table 2), including HER2 and HER3. Although HER2 receptor
overexpression occurs in around 30% of NSCLCs, the results of tri-
als with anti-HER2 agents have not been encouraging [71,72]. As
phosphorylation of EGFR is frequently through HER3 [73], addition
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Table  3
Challenges in NSCLC and suggestions for addressing them.
Challenge Proposal for addressing
Healthcare policies, medical approaches and funding vary
across  Europe, limiting advances in oncology healthcare
provision
Oncology platforms (e.g. EORTC, ESMO, ETOP, EurocarePlatform, IASLC) to co-ordinate
collaboration between healthcare professionals and industry to improve outcomes
Incidence of lung cancer varies considerably between
countries in Europe
• Collaboration between countries and centres though ETOP and other oncology platforms
•  Improvements in patient education
• Implementation of free screening and smoking cessation programmes
•  Use of customised therapies to improve outcomes
•  Identiﬁcation of enriched populations to improve clinical trial success
Quality of care differs between centres Concentration of healthcare provision in specialist centres
Mortality  rates from lung cancer have remained largely
unchanged over the past 30 years
•  Development of new treatment strategies
Implementation of strategies aimed at earlier diagnosis
Progress  in drug development in NSCLC has been slow and
the  results of many Phase III trials of targeted agents
over  the past decade have been negative
• Identiﬁcation of predictive biomarkers of response
•  Recruitment of patients on the basis of tumour biology
•  Involvement of oncology platforms such as ETOP to co-ordinate screening
Use of a combination of targeted agents to avoid cross-stimulation of signalling pathways
Survival  beneﬁts are difﬁcult to demonstrate in clinical
trials
Development of surrogate endpoints (e.g. PFS, quality of life)
The beneﬁt of adjuvant trials in NSCLC is unclear • Improvement in identiﬁcation of the patients most likely to beneﬁt from adjuvant therapy
•  Obtain better understanding of the biology of targeted agents before investigation in the
adjuvant setting
Obtain  long-term toxicity data on novel agents before undertaking adjuvant trials
The  subpopulations who will beneﬁt from particular
targeted therapies is uncertain
Identiﬁcation of predictive biomarkers of response
Intellectual  property rights can be a barrier to the clinical
use  of biomarkers and may  limit drug development for
rare  mutations
• Development of inexpensive biomarker assays in parallel with drug development
Collaboration between centres to avoid use of multiple detection methods, improve
reproducibility and avert false positives
The quality and availability of tissue samples may  be a
challenge  for the future due to routine testing for
increasing numbers of mutations
Centralise  molecular diagnostics across the oncology community to reduce costs and improve
quality control
Treatment  for stage III NSCLC is challenging due to patient
comorbidity and tumour heterogeneity
•  Development of novel treatment approaches including immunomodulatory strategies, cell cycle
agents  and novel cytostatics
Use  of ‘window of opportunity’ trials to test new agents or strategies
Resistance to TKIs develops in almost all patients and the
optimum  treatment for progression after TKI treatment
is  unclear
• Prospective studies investigating the beneﬁt of continuation of TKI treatment beyond progression
Combination of targeted agents or addition of a cytotoxic agent to a targeted agent to
delay/prevent resistance
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f an anti-HER3 drug to improve the efﬁcacy of anti-EGFR agents
as also been investigated, and trials to investigate this strategy are
ngoing.
KRAS is a frequent mutation in lung cancer tumours that was
reviously thought to be undruggable; however, recent studies
uggest alternative ways of targeting this mutation. One such
trategy involves inhibition of cyclin-dependent kinase 4 (CDK4),
ince KRAS appears to be dependent on this cell cycle progres-
ing molecule in animal models [74]. Inhibition of MEK  has also
een investigated, with a progression-free survival (PFS) bene-
t being demonstrated for the MEK  inhibitor, selumetinib, when
sed in combination with docetaxel in patients with KRAS mutant
umours [75]. The latter ﬁndings should be treated with caution,
owever, as the effects of this agent in KRAS wild-type or an
nselected population is unknown. Nevertheless, recent preclin-
cal data provide support for the combination of MEK  and BCL-XL
nhibition as a strategy for targeting KRAS [76]. Immunotherapeu-
ic strategies are also being investigated, and encouraging results
ave been demonstrated for the anti-cytotoxic T-cell lymphocyte-
 monoclonal antibody, ipilimumab, when used in combination
ith paclitaxel and carboplatin as ﬁrst-line therapy in patients with
tage III NSCLC [77]. Blockade of programmed death-1 (PD-1), a co-
nhibitory receptor expressed by activated T-cells, has also been
xamined as a strategy to overcome immune resistance and medi-
te tumour regression [78], though selection of the subpopulation
f patients who will beneﬁt from this strategy will be challenging.There  is a need for improved trial designs for the development
f new targeted agents for NSCLC, particularly when targeting
are and infrequent mutations like DNA repair deﬁciencies, with
tudies including assessment of biomarkers and involving selectedociety for Medical Oncology; ETOP, European Thoracic Oncology Platform; IASLC,
; PFS, progression-free survival; TKI, tyrosine kinase inhibitor.
populations.  Ideally, new drugs should be investigated initially
in the metastatic setting before earlier settings are studied, with
development targeting the non-smoking population in the ﬁrst
instance to maximise response.
7. Provision of healthcare services and treatment
challenges for patients with NSCLC in Europe
Improvements in the provision of oncology healthcare services
in Europe are needed due to escalating drug costs and limited funds.
While certain barriers to advances in healthcare provision exist in
Europe (differences in language, local policies, medical approaches
and funding), progress is being made, with a number of networks
being set up to report on health status across the region. These
networks (e.g. the European Oncology Thoracic Platform [ETOP],
European Organisation for the Research and Treatment of Can-
cer [EORTC] and the International Association for the Study of
Lung Cancer [IASLC]) will play a key role in improving health-
care provision in oncology in the future, enabling collaboration
between healthcare professionals and industry in order to improve
outcomes [79,80]. Such collaborations are important, since the inci-
dence of lung cancer and mortality rates differ widely across Europe
[1,81].
The advent of novel targeted therapy for patients with NSCLC has
resulted in clear progress in the treatment of this common malig-
nancy in recent years, though challenges still remain (Table 3). In
particular, optimum use of novel agents requires the identiﬁcation
of predictive markers to determine the patients who will derive
the most beneﬁt. New models for clinical trials in NSCLC are also
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equired, as the results of many Phase III trials with targeted agents
ndertaken over the last decade have been negative, primarily due
o the inclusion of unselected patients and limited understanding
f tumour biology [71,82–84]. The poor efﬁcacy observed in early
rials with targeted agents may  also be due to cross-stimulation
f the targets of these agents, such that interference with a sin-
le pathway may  not be sufﬁcient [85]. Consequently, to improve
ure rates, consideration should be given to the combination of
argeted agents, with multiple biopsies being collected to study
umour evolution over time.
In order to improve efﬁciency and reduce the cost of develop-
ent, future trials for new targeted agents in NSCLC should aim to
ecruit patients on the basis of tumour biology rather than clini-
al characteristics. Indeed the beneﬁt of this approach has already
een established, with crizotinib receiving accelerated approval
ithin 4 years following demonstration of considerable efﬁcacy
n a targeted (ALK+) population [86]. Nevertheless, involvement
f networks such as ETOP may  be needed so that trials can be
ndertaken in selected populations due to the number of patients
equired for screening. New surrogate endpoints (e.g. quality of
ife or PFS) are also needed for future trials due to the difﬁculty
n demonstrating survival beneﬁt.
Adjuvant platinum-based chemotherapy improves survival in
ompletely resected early-stage NSCLC and is now standard
reatment in this setting based on the results of phase III tri-
ls [87–90]. Nevertheless, the impact is limited and predictive
arkers are needed in order to better select the patients most
ikely to beneﬁt from adjuvant treatment. Indeed, the value of
his strategy has already been demonstrated in the IALT trial in
hich adjuvant cisplatin-based chemotherapy signiﬁcantly pro-
onged survival among patients with completely resected NSCLC
nd ERCC1-negative tumours (hazard ratio [HR] 0.65; p = 0.002),
hereas no beneﬁt was seen in ERCC1-postive patients (HR 1.14;
 = 0.40) [88]. Recently, however, this ﬁnding has been called into
uestion due to the inability of currently available ERCC1 antibodies
o detect the unique functional ERCC1 isoform [59]. Consequently,
he usefulness of ERCC1 expression in guiding treatment for NSCLC
atients is limited at present. Nevertheless, the results of several
ngoing studies investigating tailored adjuvant therapy based on
xpression of other markers (e.g. EGFR mutations and thymidylate
ynthase) are eagerly awaited. Additionally, use of immunotherapy
n the adjuvant setting is being evaluated in the MAGRIT (MAGE-
3 as Adjuvant, Non-Small Cell Lung Cancer Immunotherapy) trial.
aining a better understanding of the biology of targeted agents
nd obtaining long-term toxicity data before investigation in the
djuvant setting is also likely to improve the success of adjuvant
rials.
. Summary
Advances have been made in NSCLC management over the last
hree decades leading to small increases in 5-year survival rates
cross Europe (2–7%) [91–94], though further improvements are
eeded. However, advances in understanding of the molecular biol-
gy of the disease will help in the identiﬁcation of novel targeted
gents and development of personalised strategies for the numer-
us small subsets of deﬁned NSCLC, with progress in imaging and
reatment delivery also likely to improve outcomes. Furthermore,
t is hoped that implementation of some of the strategies identi-
ed in this article will go some way to improving the outlook for
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